Miranda-Hernández, M.P., López-Morales, C.A., Perdomo-Abúndez, F.C., Salazar-Flores, R.D., Ramírez-Ibanez, N.D., Pérez, N.O., Pérez, A.M., Revilla-Beltri, J., Flores-Ortiz, L.F. and Medina-Rivero, E. (2016) New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept. Journal of Immunology Research, 2016, Article ID: 9697080.
https://doi.org/10.1155/2016/9697080

has been cited by the following article:

• TITLE: Analytical Method Development and Validation of Etanercept by UV and RP-UFLC Methods

  AUTHORS: Husna Kanwal Qureshi, Ciddi Veeresham, Chinta Srinivas

  KEYWORDS: Biosimilars, Etanercept, Etacept®, RP-UFLC, UV Spectroscopy, Validation

  JOURNAL NAME: American Journal of Analytical Chemistry, Vol.12 No.12, December 30, 2021

  ABSTRACT: The research work was carried out using Ultraviolet (UV)—visible spectroscopy and Reverse Phase-Ultra Fast Liquid Chromatography (RP-UFLC) for establishing novel methods for the analysis and quantification of Biosimilar drug, Etanercept. The maximum absorbance of Etanercept was found to be 215 nm and it obeyed Beer-Lamberts law in the range of 5 to 200 μg/ml and 1 to 32 μg/ml for UV and RP-UFLC, respectively. The correlation coefficient (r2) value was found to be between 0.999 and 0.9995. All the validation parameters like linearity, accuracy, and precision, Limit of Detection (LOD), Limit of Quantitation (LOQ) and Robustness were found to be within acceptance criteria as per ICH guidelines. The results of accuracy studies (99.0% to 100.38%) indicated the methods to be accurate. The RSD % for interday and intraday precision studies was found to be less than 2%. Robustness and ruggedness were expressed in terms of RSD % which were also in the specified limits. LOD and LOQ of proposed method was calculated and found to be 1.257 and 3.809 μg/ml by UV, and 0.1073 μg/ml and 0.3251 μg/ml by RP-UFLC method, respectively. The developed methods were observed to be simple, rapid and cost-efficient. It can be easily applied for the estimation of Etanercept in the marketed formulations and for routine analysis of the Biosimilar drug.